Trevena Inc (TRVN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Trevena Inc (TRVN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7569
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Trevena Inc (Trevena) is a biotechnology company that discovers and develops G-protein coupled receptor targeted medicines. The company provides products such as RV027, TRV130, TRV734 and TRV250. Its TRV027 is an intravenous drug used for the treatment of acute heart failure in combination with standard diuretic therapy. Trevena’s TRV130 is an intravenous G protein biased ligand that targets the mu opioid receptor. The company’s GPCR is associated with beneficial versus adverse biological effects. Its TRV250 is an oral delta opioid biased ligand for treatment of refactory migraine. It operates in the US. Trevena is headquartered in Chesterbrook, Pennsylvania, the US.

Trevena Inc (TRVN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trevena Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Trevena Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Trevena Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Trevena To Raise US$60 Million In Series C Financing 11
Partnerships 13
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 13
Licensing Agreements 14
Jiangsu Nhwa Pharma Enters into Licensing Agreement with Trevena 14
Pharmbio Korea Enters into Licensing Agreement with Trevena 15
Equity Offering 16
Trevena to Raise up to USD50 Million in Public Offering of Shares 16
Trevena Raises USD73 Million in Public Offering of Shares 17
Trevena Raises USD51.4 Million in Public Offering of Shares 19
Trevena Completes Underwriters Exercise Of Over-Allotment Of IPO For US$66.6 Million 21
Trevena Inc – Key Competitors 23
Trevena Inc – Key Employees 24
Trevena Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Aug 02, 2018: Trevena reports second quarter 2018 financial results 26
May 03, 2018: Trevena Reports First Quarter 2018 Financial Results 28
Mar 07, 2018: Trevena Reports Full Year 2017 Earnings 29
Nov 07, 2017: Trevena Reports Third Quarter 2017 Financial Results and Announces New Positive Clinical Trial Data 31
Aug 03, 2017: Trevena Reports Second Quarter 2017 Financial Results and Provides Corporate Update 33
May 04, 2017: Trevena Reports First Quarter 2017 Financial Results and Provides Corporate Update 35
Mar 08, 2017: Trevena Reports Full Year 2016 Earnings 36
Corporate Communications 38
Oct 01, 2018: Trevena announces completion of leadership transition and appointment of new director 38
May 21, 2018: Trevena Names Mark A. Demitrack As Chief Medical Officer 39
Apr 05, 2018: Trevena Announces Retirement of Maxine Gowen and Planned Promotion of Carrie L. Bourdow to President and Chief Executive Officer 40
Feb 02, 2018: Trevena Announces Promotion Of Carrie Bourdow to Executive Vice President and Chief Operating Officer 41
Aug 14, 2017: Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 42
Clinical Trials 43
Apr 06, 2017: Trevena Announces Presentations at the 42nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting 43
Feb 21, 2017: Trevena Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute Pain 45
Jan 04, 2017: Trevena Completes Enrollment of Phase 3 APOLLO Pivotal Efficacy Trials of Oliceridine for Moderate-to-Severe Acute Pain 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Trevena Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trevena Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trevena Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Trevena Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Trevena To Raise US$60 Million In Series C Financing 11
Trevena Enters Into Research Agreement With Merck For Biased Ligand Molecules 13
Jiangsu Nhwa Pharma Enters into Licensing Agreement with Trevena 14
Pharmbio Korea Enters into Licensing Agreement with Trevena 15
Trevena to Raise up to USD50 Million in Public Offering of Shares 16
Trevena Raises USD73 Million in Public Offering of Shares 17
Trevena Raises USD51.4 Million in Public Offering of Shares 19
Trevena Completes Underwriters Exercise Of Over-Allotment Of IPO For US$66.6 Million 21
Trevena Inc, Key Competitors 23
Trevena Inc, Key Employees 24

List of Figures
Trevena Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Trevena Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Trevena Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Trevena Inc (TRVN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cipher Pharmaceuticals Inc (CPH):企業の財務・戦略的SWOT分析
    Summary Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company provides products such as actikerall, a topical solution indicated for the treatment of hyperkeratotic actinic keratosis; beteflam, a topical patch used for the treatment of mild to …
  • Eli Lilly and Co (LLY):企業の財務・戦略的SWOT分析
    Eli Lilly and Co (LLY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Trevena Inc (TRVN):企業の財務・戦略的SWOT分析
    Summary Trevena Inc (Trevena) is a biotechnology company that discovers and develops G-protein coupled receptor targeted medicines. The company provides products such as RV027, TRV130, TRV734 and TRV250. Its TRV027 is an intravenous drug used for the treatment of acute heart failure in combination w …
  • NovoCure Ltd (NVCR)-医療機器分野:企業M&A・提携分析
    Summary NovoCure Ltd (NovoCure) is an drug company that concentrates on the development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in various types of cancer indications such as ovarian cancer, malignant melanoma, hepatocellul …
  • Salvatore Ferragamo SpA (SFER):企業の財務・戦略的SWOT分析
    Salvatore Ferragamo SpA (SFER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Newfield Exploration Co (NFX):石油・ガス:M&Aディール及び事業提携情報
    Summary Newfield Exploration Co (Newfield) is an independent upstream company. The company focuses on onshore large scale, liquids-rich resource plays. Its domestic assets are in the Anadarko and Arkoma basins of Oklahoma, the Williston Basin of North Dakota and the Uinta Basin of Utah. The company …
  • Ionis Pharmaceuticals, Inc.:企業の戦略・SWOT・財務分析
    Ionis Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ionis Pharmaceuticals, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • FitLife Brands, Inc.:戦略・SWOT・企業財務分析
    FitLife Brands, Inc. - Strategy, SWOT and Corporate Finance Report Summary FitLife Brands, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • APR Energy Ltd:企業の戦略的SWOT分析
    APR Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • InterGen:企業の戦略的SWOT分析
    InterGen - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Academia Sinica:製薬・医療:M&Aディール及び事業提携情報
    Summary Academia Sinica is an academic institution that promotes and undertakes research activities in the disciplines of mathematics and physical sciences, life sciences, humanities and social sciences, and others. The institution integrates research activities to improve the planning, implementati …
  • Repsol, S.A.:企業の戦略・SWOT・財務情報
    Repsol, S.A. - Strategy, SWOT and Corporate Finance Report Summary Repsol, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Grupo Financiero Galicia S.A. (GGAL3):企業の財務・戦略的SWOT分析
    Grupo Financiero Galicia S.A. (GGAL3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Inform Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Inform Diagnostics Inc(Inform Diagnostics) formerly known as Miraca Life Sciences, a subsidiary of Miraca Holdings Inc, is an anatomic pathology laboratory that offers diagnostic services. The laboratory provides services in the areas of breast health, dermatology, gastroenterology, hematolo …
  • Faiveley Transport SA:企業の戦略的SWOT分析
    Faiveley Transport SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Mitsubishi Electric Corp (6503):企業の財務・戦略的SWOT分析
    Mitsubishi Electric Corp (6503) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Newcrest Mining Ltd:企業の戦略・SWOT・財務情報
    Newcrest Mining Ltd - Strategy, SWOT and Corporate Finance Report Summary Newcrest Mining Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Leukocare AG:医療機器:M&Aディール及び事業提携情報
    Summary Leukocare AG (Leukocare) is a clinical-stage biotechnology company that offers technologies for stabilizing proteins to increase shelf-life and to facilitate terminal sterilization by irradiation or gas. The company’s services include development of spray drying and spray freeze-drying proce …
  • Achem Technology Corporation:企業の戦略・SWOT・財務分析
    Achem Technology Corporation - Strategy, SWOT and Corporate Finance Report Summary Achem Technology Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Penske Automotive Group, Inc.:企業の戦略・SWOT・財務情報
    Penske Automotive Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Penske Automotive Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆